---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-086679"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2022-03-28T23:59:59+00:00"
generated_at: "2026-06-26T15:41:35.498975+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics CEO Mallon steps down; Q1 revenue to miss guidance; 2022 outlook withdrawn

## Summary
- CEO Mark Mallon steps down effective immediately; Board appoints Lynn Tetrault as Executive Chair, forms Office of the CEO with three executives.
- Q1 2022 revenue expected below prior guidance of $118-120M; EBITDA below guidance of ($15)-($12)M, primarily due to higher Clinical Services COGS.
- Company withdraws full-year 2022 financial guidance issued Feb 23, 2022; will report Q1 results on Apr 27.
- Separation agreement: Mallon receives $775K base salary + $775K target bonus, plus accelerated vesting of certain equity awards.
- Board retains Russell Reynolds to conduct CEO search.

## SEC filing metadata
- accession: 0001193125-22-086679
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2022-03-28T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000119312522086679/0001193125-22-086679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000119312522086679/d312815d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-086679
- JSON: https://secwatch.observer/filing/0001193125-22-086679.json
- Plain text: https://secwatch.observer/filing/0001193125-22-086679.txt

## Key facts
- Executive change
  Mark W. Mallon departed as Chief Executive Officer at NEOGENOMICS INC.
  - Action: stepped down
  - Role: Chief Executive Officer
  source text: On March 27, 2022, Mark W. Mallon, Chief Executive Officer (“CEO”) and a member of the Board of Directors (the “Board”) of NeoGenomics, Inc. (the “Company”), stepped down from his positions as CEO and director, effective as of March 28, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000119312522086679/0001193125-22-086679-index.htm
- Executive change
  Lynn A. Tetrault was appointed as Executive Chair at NEOGENOMICS INC.
  - Action: appointed
  - Role: Executive Chair
  source text: the Board appointed Lynn A. Tetrault, Esq. the Company’s non-executive Chair of the Board and Chair of the Culture and Compensation Committee, to serve as Executive Chair and the Company’s principal executive officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000119312522086679/0001193125-22-086679-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.